Home Healthcare Pharmaceuticals Anti-VEGF Therapeutics Market

Anti-VEGF Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu, Vabysmo, Others), By Disease Type (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Myopic Choroidal Neovascularization) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 05, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-VEGF Therapeutics Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Eylea
    2. Lucentis
    3. Beovu
    4. Vabysmo
    5. Others
  2. Anti-VEGF Therapeutics Market, By Disease Type 2022-2034 (USD MILLION/ Units)
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-related Macular Degeneration
    5. Myopic Choroidal Neovascularization
  3. Regional Anti-VEGF Therapeutics Market
    1. North America
      1. North America Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. North America Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. U.S.
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      4. Canada
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
    2. Europe
      1. Europe Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. Europe Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. U.K.
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      4. Germany
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      5. France
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      6. Spain
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      7. Italy
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      8. Russia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      9. Nordic
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      10. Benelux
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      11. Rest of Europe
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
    3. APAC
      1. APAC Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. APAC Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. China
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      4. Korea
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      5. Japan
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      6. India
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      7. Australia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      8. Taiwan
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      9. South East Asia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      10. Rest of Asia-Pacific
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
    4. Middle East and Africa
      1. Middle East and Africa Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. Middle East and Africa Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. UAE
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      4. Turkey
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      5. Saudi Arabia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      6. South Africa
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      7. Egypt
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      8. Nigeria
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      9. Rest of MEA
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
    5. LATAM
      1. LATAM Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. LATAM Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. Brazil
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      4. Mexico
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      5. Argentina
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      6. Chile
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      7. Colombia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
      8. Rest of LATAM
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
        6. Macular Edema
        7. Diabetic Retinopathy
        8. Retinal Vein Occlusion
        9. Age-related Macular Degeneration
        10. Myopic Choroidal Neovascularization
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.